Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Switching to Tenolid from Viread in Chronic Hepatitis B
NCT05286346Phase 4Completed
- Sponsor
- Samjin Pharmaceutical Co., Ltd.
- Start
- Oct 2018
- Primary completion
- Aug 2020
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in hepatitis B (HBV) (2 arms), sponsored by Samjin Pharmaceutical Co., Ltd. Primary endpoint: Inhibiting rate of HBV virus (HBV DNA < 400 copies/mL) at 48 weeks. Started Oct 2018; status: completed.
02
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT05286346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05286346.